joining everyone, call for Welcome, our Avadel's earnings. year thank discuss quarter conference to and and XXXX full you us on Fourth
Tom opening we and full and XXXX year a my our QX will results Following conclude session. financial with question-and-answer will review remarks,
Many of we preliminary a and our for with line where and financial are in you announcement, call we and final QX of XXXX. update reiterating the guidance today our results for year XXXX. are in January, unaudited full corporate The provided released joined results that previous
by on secure on the providing Before capitalize operational Tom LUMRYZ leadership color opportunity to and begin discuss doing that, space. LUMRYZ and some marketplace progress to to the and in strategic sleep in our gets want I is how our the fully
only commercial same approximately launched added nearest over months record competitor the for which LUMRYZ organization, built months, to over oxybate X,XXX Xx approval. XX-plus we LUMRYZ, few period. of is into have a time We're an on that since patients net our approximately our post in time launch. weeks And X In now a
at therapy look launch, reported mixed XX% to of as the reflects nearly and patient market onto Or LUMRYZ's proposition as the the as another consistent value uptake LUMRYZ This either unique since ] salt total interest been twice launch, [ is are of LUMRYZ's X,XXX to or since December way clinical of added the X,XXX types LUMRYZ patients product strong in net LUMRYZ well from the driven demand of has them prescribers. which by nearly on nightly all XX.
highlights are first-generation the launch, billion as strong. the bedtime Patient in achieve, its once only value our we feature confidence have market opportunity recognizes a and much dosing months oxybate. FDA Recognizing into XX-plus consistently However, all to $X LUMRYZ to and superior physician feedback still our at of remains clinically we
we accelerate our launch very towards potential. LUMRYZ's are advance refined full confident commercial realizing will and investments Furthermore, our recent strategy that and our progress
fact, are seeing early In of we shift this signs already.
Although the most internal or it momentum to demand-based is recent metrics, patient are at year, our data and expectations. on above our still early important in point tracking our which most currently promising trends
and are on the newly to focus based commercial confirms on continue the through and both because This investments demand added encouraging is our we system. expect their we While on into more as move quarter, begun apparent impact these and the as quarter we appear these second have to hold to during revenues beyond taking improvements first become patients funnel that see point. underlying it the
let ongoing investments our that, our launch, accelerate including key XXXX. priorities strategy, the programs cycle management refined the commercial for recap to With me life and
patient patients, X see adoption across We switch those oxybate. [ ] broad segments, naive oxybate previously discontinued continue and who all to on
been the group competing market, XX% less targeting of early is nearly expanding with patient of a market. patients have treated it. strategy, X/X and our Yet date. group instrumental overall the launch confirms growth this just not than new adopters that aligning oxybate represents starts oxybate of driving to within The core in oxybate reinitiating And XXX LUMRYZ to LUMRYZ early previously
As are and such, trends. reflected our remains and key significant opportunity us growth who a prescriber across of XXXX is in for in focus some oxybate these early the adopters broader positive base,
launch Our to a set demand experience. continued up the built has optimize and strategy these growth, by targeted strong driven for patient investments foundation accelerate LUMRYZ
generating in new-to-brand leadership By achieving patient XXXX with flow generation positive and market and segments all beyond. the cash while patients growth sustained delivering from
learnings key while ongoing As we the our enter enhancing months leadership, for we're next XX search phase, a including this commercial from commercial first leader. applying the new
greater This expansion includes in customer enable our specific nursing team, support team our our and of teams provider, it have caregiver to support whether patient, team. our sales We engagement, the be customer-facing invested other. or field
These LUMRYZ. among higher LUMRYZ potential and help deploy investments reach enable services our us will transition onto personal prescribers frequent and more to touch, more expand patients to support better
services, Avadel and see leaders commercial and qualified a services, many of the will provide veterans rates. our track proven on for We've our the relevant enhanced are anticipated fully hiring respectively. and with of We're new as also commercial through industry level our pleased recently and commercial announced with They including organizational patient talented distribution to who reimbursement experience appropriate, leadership both additional high X new both patient focused and driving highly hires patients leader. interest updates demand in team supporting are
update beyond our to provide narcolepsy, key on I'd LUMRYZ an Moving like initiatives. and other
drivers We value also creation the believe will be company. for of important
evaluating in track progressing III REVITALYZ LUMRYZ our enrollment First, IH. on and hypersomnia, Phase in or idiopathic is trial
potential as opportunity significant continue proposition can in of by half second data thereafter. routinely We that here as possible value for LUMRYZ's an a line in the have greater community. expect year, a first this followed soon even part the IH enrollment complete the filing top we Avadel as represents IH potentially impact to of NDA to XXXX, in
options. to second patients it ] less the physicians, additional due This wake care to of diagnosed take are the nightly and the than approximately receive treatment [ up the makes primarily being therapeutic deep the underscoring under twice the FDA-approved treatment, which XX% dose only by a the patients of IH benefit inertia of face, need treatment. to treated IH is XX,XXX middle to The night in for full sleep challenging a further
patient additional treatment with could innovation. those low be or eligible benefit to sodium addition a hypersomnia are sodium our of target continuing once-nightly ongoing expand proprietary In or compelling LUMRYZ trial, position from to suffering profile a our and on low market. Of product oxybate at our patient-centric related population would no to bioequivalent bedtime formulation in disorders for formulation technology work that our patients potential appropriate our no with the option the we IH maximize would competitive once an who
case once in lastly, litigation. [ to case, pending remain legal injunction related confident ruling, our And currently to which court reflecting is strategy ongoing ] trial our in novel scheduled protect the a antitrust our we of our is filed bedtime for early innovation. this This infringement appellate Jat November suits against our actions that the year. jury includes and patent at recently
last after we've proud to we wrap months wake of important improving avoid sleep. and progress these night, chronic goal focused over using We're a on people up very antithetical the opportunity the is twice-nightly of of to condition are deliver night dosing of have FDA the regimen stated help the made To and burden having to middle LUMRYZ. XX up, promise on forcibly narcolepsy to that believe the significant night a in most reduce will priorities to treat oxybate the eligible the the
translate expectations, our into and it to turn progress results to Now our over me let Tom.
